Skip to content

Outset Medical, Inc.: financial reference

Explore Outset Medical, Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Limits of the selected measures

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic: This weighted-average share observation is withheld because the original statement labels share counts in thousands, while its inline tag omits the scale attribute and encodes the displayed count in unit shares. The conflicting source presentation is retained; no multiplication, replacement value or split adjustment has been applied.

Inspect 3 withheld observations (period ends: 2023-12-31 to 2025-12-31)
Withheld source values: WeightedAverageNumberOfSharesOutstandingBasic. These values are excluded from the selected history.
Period startPeriod endOriginal valueUnitSource filing
2023-01-012023-12-313305shares0001193125-26-051278
2024-01-012024-12-313463shares0001193125-26-051278
2025-01-012025-12-3115211shares0001193125-26-051278

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding: This weighted-average share observation is withheld because the original statement labels share counts in thousands, while its inline tag omits the scale attribute and encodes the displayed count in unit shares. The conflicting source presentation is retained; no multiplication, replacement value or split adjustment has been applied.

Inspect 3 withheld observations (period ends: 2023-12-31 to 2025-12-31)
Withheld source values: WeightedAverageNumberOfDilutedSharesOutstanding. These values are excluded from the selected history.
Period startPeriod endOriginal valueUnitSource filing
2023-01-012023-12-313305shares0001193125-26-051278
2024-01-012024-12-313463shares0001193125-26-051278
2025-01-012025-12-3115211shares0001193125-26-051278

Context from the filing

For Outset Medical in 2023–2025, awards under its equity compensation plan and warrants are excluded from diluted loss per share as anti-dilutive during losses. This review covers only reported USD EPS. The separate weighted-average share observations remain withheld because their inline tags conflict with the statement’s thousands heading. No scaling, split adjustment or EPS recomputation is applied to resolve that share-count conflict. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assetsAt date2025-12-31264,496,000USD2026-02-13
Total liabilitiesAt date2025-12-31137,544,000USD2026-02-13
Stockholders equityAt date2025-12-31126,952,000USD2026-02-13
Cash and cash equivalentsAt date2025-12-3135,006,000USD2026-02-13
Net income or loss2025-01-012025-12-31-81,653,000USD2026-02-13
Operating cash flow2025-01-012025-12-31-46,327,000USD2026-02-13
Capital expenditure payments2025-01-012025-12-31798,000USD2026-02-13
Contract revenue excluding tax2025-01-012025-12-31119,476,000USD2026-02-13
Financing cash flow2025-01-012025-12-3155,503,000USD2026-02-13
Investing cash flow2025-01-012025-12-31-97,684,000USD2026-02-13
Retained earnings or deficitAt date2025-12-31-1,171,376,000USD2026-02-13
Basic weighted-average shares2022-01-012022-12-3148,161shares2025-02-28
Diluted weighted-average shares2022-01-012022-12-3148,161shares2025-02-28
Basic earnings per share2025-01-012025-12-31-5.37USD/shares2026-02-13
Diluted earnings per share2025-01-012025-12-31-5.37USD/shares2026-02-13
Income tax expense or benefit2025-01-012025-12-31718,000USD2026-02-13
Net property, plant and equipmentAt date2025-12-314,670,000USD2026-02-13
Share-based compensation expense2025-01-012025-12-3115,616,000USD2026-02-13
Operating income or loss2025-01-012025-12-31-66,706,000USD2026-02-13
Current assetsAt date2025-12-31250,883,000USD2026-02-13
Interest expense2025-01-012025-12-3113,952,000USD2026-02-13
Current liabilitiesAt date2025-12-3137,630,000USD2026-02-13
Current accounts payableAt date2025-12-31554,000USD2026-02-13
Net current accounts receivableAt date2025-12-3128,329,000USD2026-02-13
Operating expenses2025-01-012025-12-31113,460,000USD2026-02-13
Net inventoryAt date2025-12-3147,609,000USD2026-02-13
Gross profit2025-01-012025-12-3146,754,000USD2026-02-13
Research and development expense2025-01-012025-12-3121,235,000USD2026-02-13

Inspect the source

Entity
Outset Medical, Inc. / CIK 0001484612
Captured
2026-09-20T09:09:18.471Z
SEC response SHA-256
02af597b3235cdde453b8e191f935ab9286843fac1669b188d8e36c1d501f70c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001484612.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))